Facial paralysis
diseaseOn this page
Also known as face palsypalsy of face
Summary
Facial paralysis (MONDO:0001835) is a disease and 21 clinical trials. Top therapeutic interventions include oxymetazoline, botulinum toxin type a, and methoprene. A subtype of palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | facial paralysis |
| Mondo ID | MONDO:0001835 |
| MeSH | D005158 |
| DOID | DOID:13934 |
| SNOMED CT | 280816001 |
| UMLS | C0015469 |
| MedGen | 5101 |
| Anatomy (UBERON) | UBERON:0001456 |
| Is cancer (heuristic) | no |
Also known as: face palsy · palsy of face
Disease family
This is a subtype of palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy › facial paralysis
Related subtypes (9): hemiplegia, quadriplegia, ophthalmoplegia, paraplegia, cerebral palsy, progressive bulbar palsy, klumpke’s paralysis, respiratory paralysis, Erb palsy
Subtypes (2): exophthalmic ophthalmoplegia, Bell’s palsy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 19 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05945615 | PHASE3 | COMPLETED | Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis |
| NCT05293522 | PHASE2 | TERMINATED | A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. |
| NCT03115203 | Not specified | RECRUITING | Morphometric Study of the Muscles of the Skin in MRI 3 Tesla in Patients With Facial Paralysis. |
| NCT04934176 | Not specified | RECRUITING | 3D Dynamic and Patient-Centered Outcomes of Facial Reanimation Surgery in Patients With Facial Paralysis |
| NCT06335719 | Not specified | RECRUITING | Intraoperative Electrical Stimulation to Improve Nerve Grafting Outcome |
| NCT07127016 | Not specified | NOT_YET_RECRUITING | Mindfulness in Nonflaccid Facial Paralysis |
| NCT07436624 | Not specified | ACTIVE_NOT_RECRUITING | Kabat Rehabilitation Versus Kinesiology Taping in Bell’s Palsy |
| NCT00989209 | Not specified | COMPLETED | Myofunctional Therapy in Facial Palsy |
| NCT01537952 | Not specified | COMPLETED | Microbiologic Findings of Acute Facial Palsy in Children |
| NCT02527226 | Not specified | COMPLETED | Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors |
| NCT02988856 | Not specified | COMPLETED | Magnetic Correction of Eye Lid Paralysis |
| NCT03622697 | Not specified | WITHDRAWN | Effects of Mindfulness Meditation on Facial Paralysis Patients |
| NCT03974763 | Not specified | COMPLETED | Function and Form Outcomes in Patients With Facial Paralysis |
| NCT04153916 | Not specified | COMPLETED | Artificial Eye Blinking Stimulation Following Paralysis of the Facial Nerve |
| NCT04215562 | Not specified | UNKNOWN | Outcome of Facial Palsy Following Rehabilitation |
| NCT05191719 | Not specified | UNKNOWN | Neurotomy to Treat Synkinesis Following Peripheral Facial Palsy |
| NCT05222698 | Not specified | UNKNOWN | Free Neurovascularized Muscle Transfer in Facial Reanimation of Long-standing Facial Palsy Patients |
| NCT05585333 | Not specified | COMPLETED | Photobiomodulation Therapy Treatment on Facial Paralysis |
| NCT05997199 | Not specified | COMPLETED | The Effect Vitamin D on the Recovery Rate of Bell Palsy |
| NCT06538103 | Not specified | COMPLETED | Eye Soft Surgery for Facial Sinkynesis |
| NCT07305285 | Not specified | COMPLETED | Roy Adaptation Model Improves Mood and QOL After Giant Acoustic Neuroma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OXYMETAZOLINE | 4 | 3 |
| BOTULINUM TOXIN TYPE A | 4 | 1 |
| METHOPRENE | 2 | 1 |
Related Atlas pages
- Drugs: Oxymetazoline, Botulinum Toxin Type A